UBS Group’s Co-Diagnostics CODX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.7K | Buy |
7,368
+6,320
| +603% | +$21.6K | ﹤0.01% | 8205 |
|
|
2025
Q4 | $5.32K | Sell |
1,048
-2,893
| -73% | -$31.5K | ﹤0.01% | 8697 |
|
|
2025
Q3 | $40.7K | Buy |
3,941
+3,899
| +9,283% | +$36.3K | ﹤0.01% | 7708 |
|
|
2025
Q2 | $351 | Sell |
42
-210
| -83% | -$1.97K | ﹤0.01% | 9860 |
|
|
2025
Q1 | $2.34K | Buy |
252
+195
| +342% | +$3.73K | ﹤0.01% | 9356 |
|
|
2024
Q4 | $1.28K | Sell |
57
-369
| -87% | -$11.7K | ﹤0.01% | 9273 |
|
|
2024
Q3 | $16K | Sell |
426
-325
| -43% | -$12.5K | ﹤0.01% | 7491 |
|
|
2024
Q2 | $28.2K | Buy |
751
+655
| +682% | +$23.8K | ﹤0.01% | 7099 |
|
|
2024
Q1 | $3.24K | Sell |
96
-216
| -69% | -$7.83K | ﹤0.01% | 7759 |
|
|
2023
Q4 | $12.4K | Buy |
312
+309
| +10,300% | +$10.9K | ﹤0.01% | 7351 |
|
|
2023
Q3 | $106 | Sell |
3
-38
| -93% | -$1.44K | ﹤0.01% | 8869 |
|
|
2023
Q2 | $1.38K | Sell |
41
-139
| -77% | -$5.32K | ﹤0.01% | 7934 |
|
|
2023
Q1 | $8.01K | Buy |
180
+34
| +23% | +$2.73K | ﹤0.01% | 7761 |
|
|
2022
Q4 | $11K | Sell |
146
-137
| -48% | -$12.8K | ﹤0.01% | 8445 |
|
|
2022
Q3 | $27K | Buy |
+283
| New | +$39.6K | ﹤0.01% | 6984 |
|
|
2022
Q2 | – | Sell |
-50
| Closed | -$9K | – | 10385 |
|
|
2022
Q1 | $9K | Sell |
50
-826
| -94% | -$171K | ﹤0.01% | 8536 |
|
|
2021
Q4 | $235K | Buy |
876
+319
| +57% | +$83.7K | ﹤0.01% | 5547 |
|
|
2021
Q3 | $163K | Sell |
557
-459
| -45% | -$134K | ﹤0.01% | 5474 |
|
|
2021
Q2 | $251K | Sell |
1,016
-236
| -19% | -$60.7K | ﹤0.01% | 5193 |
|
|
2021
Q1 | $358K | Buy |
1,252
+1,039
| +488% | +$415K | ﹤0.01% | 5100 |
|
|
2020
Q4 | $59K | Buy |
213
+48
| +29% | +$17.8K | ﹤0.01% | 6036 |
|
|
2020
Q3 | $67K | Sell |
165
-594
| -78% | -$305K | ﹤0.01% | 5436 |
|
|
2020
Q2 | $440K | Buy |
759
+751
| +9,388% | +$343K | ﹤0.01% | 4253 |
|
|
2020
Q1 | $2K | Buy |
+8
| New | +$1.39K | ﹤0.01% | 7602 |
|
|
2019
Q4 | – | Sell |
-23
| Closed | -$1K | – | 8136 |
|
|
2019
Q3 | $1K | Sell |
23
-237
| -91% | -$7.88K | ﹤0.01% | 7820 |
|
|
2019
Q2 | $6K | Buy |
260
+213
| +453% | +$5.96K | ﹤0.01% | 7303 |
|
|
2019
Q1 | $2K | Sell |
47
-103
| -69% | -$3.71K | ﹤0.01% | 7425 |
|
|
2018
Q4 | $7K | Buy |
150
+50
| +50% | +$3.27K | ﹤0.01% | 7400 |
|
|
2018
Q3 | $8K | Buy |
100
+26
| +35% | +$2.57K | ﹤0.01% | 7268 |
|
|
2018
Q2 | $9K | Sell |
74
-88
| -54% | -$7.18K | ﹤0.01% | 7182 |
|
|
2018
Q1 | $11K | Buy |
162
+131
| +423% | +$10K | ﹤0.01% | 6802 |
|
|
2017
Q4 | $2K | Buy |
+31
| New | +$4.64K | ﹤0.01% | 7601 |
|
Other funds holding CODX
PAG
SAM
SS
HWA
DB
NA
UBS Group's CODX Position: Q1 2026 in Review
UBS Group increased its Co-Diagnostics (CODX) stake by 603% in Q1 2026, buying an estimated $21.6K and bringing the position to 7,368 shares worth $13.7K. The position accounts for ﹤0.01% of the portfolio, ranked #8205.
UBS Group first reported a position in CODX in Q4 2017 and has held it in 32 quarters since. The position peaked at $440K in Q2 2020. 14 funds tracked by Wall St. Rank hold CODX as of Q1 2026.
- UBS Group held 7,368 shares of Co-Diagnostics worth $13.7K as of Q1 2026.
- UBS Group bought 6,320 Co-Diagnostics shares in Q1 2026, an estimated $21.6K.
- Co-Diagnostics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8205 holding.
- UBS Group first reported a position in Co-Diagnostics in Q4 2017 and has held it in 32 quarters since.
- UBS Group's Co-Diagnostics position peaked at $440K in Q2 2020.
- 14 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.